Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022, on Monday, May 16, 2022, beginning at 4:30 p.m. ET.
The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
To ask a question ahead of the presentation, please submit them to @Ginkgo on Twitter (hashtag #GinkgoResults) or by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it..
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit https://www.ginkgobioworks.com/.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.11 |
Daily Change: | -0.09 -0.80 |
Daily Volume: | 1,411,872 |
Market Cap: | US$502.170M |
November 12, 2024 November 12, 2024 September 24, 2024 September 18, 2024 September 17, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load